Dr. Coleman, together with Dr. Wimmer and Dr. Mueller co-discovered the SAVE technology and co-founded Codagenix, Inc. His work focuses on rational gene design for vaccine construction. He has multiple high impact publications, is the primary investigator on externally funded research projects, and has project management skills in small business and biotechnology. Dr. Coleman completed his MBA in finance while simultaneously co-founding Codageni

Dr. Mueller could be considered a preeminent synthetic virologist. Prior to synthetic virology he studied aspects of virus/host interaction, and the cell biology of virus receptors. Together with Dr. Wimmer and Dr. Coleman, Mueller co-developed SAVE, a rational computer-aided approach of designing synthetic, attenuated pathogens. Mueller, Wimmer and Coleman co-founded Codagenix Inc. to develop improved live attenuated human vaccines of medical n

Dr. Wimmer was recently inducted into the National Academy of Sciences in recognition of his accomplishments as a molecular biologist who has been an expert on viral pathogenesis for over forty years. In the course of these studies Dr. Wimmer has deciphered the genome sequence and genetic structure of poliovirus, the antigenic structure of the poliovirion, and the viral IRESs. Recently, he has co-developed the SAVE platform strategy of whole gen